TP53 and melanoma: This drug has since been used for testing S100B inhibition in numerous disease states, including in a human clinical trial for malignant melanoma (0794GCC: “Treatment of Melanoma with Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial with Correlative Biomarker Endpoints”; NCT00729807) [23,24,25].